However, antibodies against the VNTR epitope have not yet yielded results in clinical trials, which have failed mainly due to the shedding of the VNTR epitope and its release into the circulation, thus preventing the binding of antibodies to the structural domain of MUC1 on the surface of cancer cells [174]. The gene discussed is MUC1; the disease is cancer.